| scholarly article | Q13442814 |
| P50 | author | Daniel Haber | Q5217393 |
| Keith Flaherty | Q6384357 | ||
| Jennifer Wargo | Q32650026 | ||
| Mari Mino-Kenudson | Q40930518 | ||
| Rosalynn M. Nazarian | Q51791961 | ||
| Aaron N Hata | Q80043157 | ||
| Shyamala Maheswaran | Q89582233 | ||
| Adriano Piris | Q125315301 | ||
| P2093 | author name string | John Walsh | |
| Ronald D. Brown | |||
| Jeffrey Settleman | |||
| Daniel Winokur | |||
| Keith T. Flaherty | |||
| Daniel A. Haber | |||
| Jennifer A. Wargo | |||
| Anthony C. Faber | |||
| Ryan B. Corcoran | |||
| Stephen Michael Rothenberg | |||
| Jeffrey A. Engelman | |||
| Jason T. Godfrey | |||
| P2860 | cites work | Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase | Q24564747 |
| Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib | Q24594790 | ||
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations | Q24632064 | ||
| The PI3K pathway as drug target in human cancer | Q24632283 | ||
| Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling | Q24672005 | ||
| The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer | Q27651832 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation | Q27851610 | ||
| Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis | Q28246808 | ||
| Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks | Q28255399 | ||
| The LKB1 tumor suppressor negatively regulates mTOR signaling | Q28272728 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation | Q29615032 | ||
| A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen | Q29615061 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 | ||
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion | Q29617359 | ||
| Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| mTOR signaling at a glance | Q29619857 | ||
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) | Q29620033 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. | Q34032640 | ||
| BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. | Q35588268 | ||
| Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF | Q35700459 | ||
| Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance | Q36489360 | ||
| RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation | Q36745240 | ||
| Surgery and radiotherapy in the treatment of cutaneous melanoma | Q37266677 | ||
| Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. | Q37396608 | ||
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer | Q37605004 | ||
| Fine-needle biopsy of metastatic melanoma: clinical use and new applications | Q37682482 | ||
| mTOR signaling and drug development in cancer | Q37710367 | ||
| Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers | Q37866945 | ||
| BRAF Inhibitors and Melanoma | Q37966920 | ||
| From genes to drugs: targeted strategies for melanoma | Q37999967 | ||
| Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. | Q40102679 | ||
| Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. | Q40662652 | ||
| Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 | ||
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
| P433 | issue | 196 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 196ra98 | |
| P577 | publication date | 2013-07-01 | |
| 2013-07-31 | |||
| P1433 | published in | Science Translational Medicine | Q1573955 |
| P1476 | title | TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma | |
| TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma | |||
| P478 | volume | 5 |
| Q42632563 | 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. |
| Q92794476 | A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma |
| Q52678458 | A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. |
| Q38903238 | A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. |
| Q54108752 | Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. |
| Q36350128 | BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer |
| Q35090029 | BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model |
| Q34004428 | CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers |
| Q92415836 | Cathepsin K inhibition-induced mitochondrial ROS enhances sensitivity of cancer cells to anti-cancer drugs through USP27x-mediated Bim protein stabilization |
| Q50042437 | Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines |
| Q35408594 | Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma |
| Q42085487 | Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer |
| Q26799864 | Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet |
| Q30277902 | Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas |
| Q27853216 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. |
| Q50066241 | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer |
| Q36775204 | Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer |
| Q94545877 | Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells |
| Q37009001 | Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma |
| Q92254021 | Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models |
| Q61808023 | Cumingianoside A, a Phyto-Triterpenoid Saponin Inhibits Acquired BRAF Inhibitor Resistant Melanoma Growth via Programmed Cell Death |
| Q90167681 | Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer |
| Q28540161 | Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor |
| Q92632442 | Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity |
| Q27324821 | Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer |
| Q27852994 | Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma |
| Q37457602 | Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models |
| Q38145387 | Emerging BRAF inhibitors for melanoma. |
| Q38964435 | Emerging role of mTOR in the response to cancer therapeutics |
| Q35670413 | Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells |
| Q37190236 | Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors |
| Q90459618 | Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations |
| Q58197295 | Head and neck cancer: from research to therapy and cure |
| Q36104106 | Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method. |
| Q36092925 | Identification of a Dual Inhibitor of Janus Kinase 2 (JAK2) and p70 Ribosomal S6 Kinase1 (S6K1) Pathways |
| Q30982375 | Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data |
| Q36033783 | Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma |
| Q35746524 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth |
| Q38238605 | Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer |
| Q34103998 | Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor |
| Q64885369 | Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. |
| Q37705948 | LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer |
| Q27313653 | Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment |
| Q39329582 | Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma |
| Q37262481 | Mechanisms of targeted therapy resistance take a de-TOR. |
| Q36429062 | Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth |
| Q26775598 | Melanoma: oncogenic drivers and the immune system |
| Q38955884 | Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma |
| Q38245356 | No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients |
| Q44943545 | Oncogene-inducible organoids as a miniature platform to assess cancer characteristics |
| Q30080017 | PI3K and cancer: lessons, challenges and opportunities |
| Q43236110 | PI3K pathway inhibition in GBM—is there a signal? |
| Q26865736 | Pathways and therapeutic targets in melanoma |
| Q38718552 | Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. |
| Q97595565 | Proteome activity landscapes of tumor cell lines determine drug responses |
| Q38836377 | RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma |
| Q37544392 | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells |
| Q89835976 | Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications |
| Q34417585 | Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation. |
| Q33946905 | Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis |
| Q132042932 | Ribosomal Protein S6: A Potential Therapeutic Target against Cancer? |
| Q38894416 | Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis |
| Q38235584 | Systemic treatment for BRAF-mutant melanoma: where do we go next? |
| Q38194591 | Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond |
| Q38856722 | Targeted agents and immunotherapies: optimizing outcomes in melanoma |
| Q26865765 | Targeting cancer with kinase inhibitors |
| Q27010154 | The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics |
| Q46546002 | The PI3K Pathway in Human Disease |
| Q38917126 | The role of eIF4E in response and acquired resistance to vemurafenib in melanoma |
| Q33978378 | Understanding the biology of melanoma and therapeutic implications |
| Q34662717 | Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma |
| Q37492231 | hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma |
| Q39456830 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. |
| Q47152492 | mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. |
| Q35236736 | mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma |
| Q60395350 | mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer |
| Q99564796 | mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability |
| Q37605004 | mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer |
| Q38142727 | mTORC1 status dictates tumor response to targeted therapeutics. |
| Q47352692 | mTORC1 suppresses PIM3 expression via miR-33 encoded by the SREBP loci. |
| Q38907215 | mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells. |
| Q42378326 | mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition |
| Q48769194 | p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis |
Search more.